Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer

Cancer

Volumn 83, Issue 4, 1998, Pages 797-805

  Kammula, Udai S ^a   White, Donald E ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Immunotherapy; Interleukin 2; Melanoma; Renal cell cancer; Safety; Toxicity

Indexed keywords

INTERLEUKIN 2;

ARTICLE; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER SCREENING; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS;

EID: 0031812910     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M     Document Type: Article

References (26)

1. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907-13.
2. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. JAMA 1986;256: 3117-24.
3. White RL Jr., Schwartzentruber DJ, Guleria A, MacFarlane MP, White DE, Tucker E, et al. Cardiopulmonary toxicity of treatment with high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 1994;74:3212-22.
4. Schwartzentruber DJ. Biologic therapy with interleukin-2: clinical applications. Principals of administration and management of side effects. In: DeVita VT, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. 2 ed. Philadelphia: J.B. Lippincott, 1995:235-49.
5. Guleria AS, Yang JC, Topalian SL, Weber JS, Parkinson DR, MacFarlane MP, et la. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol 1994;12:2714-22.
6. MacFarlane MP, White RL Jr., Seipp CA, Einhorn JH, White DE, Rosenberg SA. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma. Cancer 1995;75:1030-7.
7. Krouse RS, Royal RE, Heywood G, Weintraub BD, White DE, Steinberg SM, et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother 1996;18:272-8.
8. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Lineham WM, Seipp CA, et al. Experience with the use of high-dose interleukni-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-85.
9. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer [published erratum appears in J Natl Cancer Inst 1993;85(13):1091]. J Natl Cancer Inst 1993;85: 622-32.
10. Yang JC, Topalian SL, Schwartzentruber DJ, Parkinson DR, Marincola FM, Weber JS, et al. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A Phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer 1995;76:687-94.
11. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 1994;86: 1159-66.
12. Lotze MT, Matory YL, Rayner AA, Ettinghausen SK, Vetto JT, Seipp CA, et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986;58:2764-72.
13. Webb DE, Austin HA III, Belldegrun A, Vaughan E, Linehan WM, Rosenberg SA. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin Nephrol 1988;30:141-5.
14. Belldegrun A, Webb DE, Austin HA III, Steinberg SM, White DE, Linehan WM, et al. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 1987;106:817-22.
15. Belldegrun A, Webb DE, Austin HA III, Steinberg SM, Linehan WM, Rosenberg SA. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. J Urol 1989;141:499-503.
16. Ognibene FP, Rosenberg SA, Lotze M, Skibber J, Parker MM, Shelhamer JH, et al. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 1988; 94:750-4.
17. Nora R, Abrams JS, Tait NS, Hiponia DJ, Silverman HJ. Myocardial toxic effects during recombinant interleukin-2 therapy. J Natl Cancer Inst 1989;81:59-63.
18. Lee RE, Lotze MT, Skibber JM, Tucker E, Bonow RO, Ognibene FP, et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 1989;7:7-20.
19. Ettinghausen SE, Moore JG, White DE, Platanias L, Young NS, Rosenberg SA. Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 1987;69:1654-60.
20. Pockaj BA, Topalian SL, Steinberg SM, White DE, Rosenberg SA. Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. J Clin Oncol 1993;11:136-47.
21. Klempner MS, Noring R, Mier JW, Atkins MB. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 1990;322:959-65.
22. Jablons D, Bolton E, Merlins S, Rubin M, Pizzo P, Rosenberg SA, et al. Il-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis. J Immunol 1990;144:3630-6.
23. Bock SN, Lee RE, Fisher B, Rubin JT, Schwartzentruber DJ, Wei JP, et al. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol 1990;8:161-9.
24. Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987;107:293-300.
25. Ettinghausen SE, Puri RK, Rosenberg SA. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 1988;80:177-88.
26. Royal RE, Steinberg SM, Krouse RS, Heywood G, White DE, Hwu P, et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am 1996;2:91-8.